乳酸多韦替尼

乳酸多韦替尼（CAS 915769-50-5）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

• Investigated for use/treatment in multiple myeloma and solid tumors.
• Unlike many kinase inhibitors that only target vascular endothelial growth factor (VEGF), Dovitinib inhibits receptors in the fibroblast growth factor (FGF ) pathway, as well as VEGF and platelet-derived growth factor (PDGF). FGF receptor tyrosine kinase inhibition is potentially of therapeutic significance to a group of myeloma patients whose cancer cells express high levels of surface FGF receptors.

同义词与商品名

Dovitinib; 405169-16-6; TKI-258; I35H55G906; GFKI-258; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydroquinolin-2-one; dovitinibum; 4-amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl)-1,2-dihydroquinolin-2-one; RefChem:590385; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; Dovitinib [INN]; Chir 258; Dovitinib (TKI-258, CHIR-258); Dovitinib (TKI-258); Dovitinib lactate; 4-Amino-5-Fluoro-3-(6-(4-Methylpiperazin-1-yl)-1H-Benzo[D]Imidazol-2-yl)Quinolin-2(1H)-One

公开数据库对它的描述

Dovitinib lactate · CAS 915769-50-5 · C21H21FN6O. UNII I35H55G906.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。